[go: up one dir, main page]

FR2882265A1 - Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2. - Google Patents

Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.

Info

Publication number
FR2882265A1
FR2882265A1 FR0505228A FR0505228A FR2882265A1 FR 2882265 A1 FR2882265 A1 FR 2882265A1 FR 0505228 A FR0505228 A FR 0505228A FR 0505228 A FR0505228 A FR 0505228A FR 2882265 A1 FR2882265 A1 FR 2882265A1
Authority
FR
France
Prior art keywords
prevention
preparation
treatment
diabetes
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0505228A
Other languages
English (en)
Other versions
FR2882265B1 (fr
Inventor
Corinne Hanotin
Pierre Rosenzweig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0501861A external-priority patent/FR2882261B1/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR0505228A priority Critical patent/FR2882265B1/fr
Priority to TW095105631A priority patent/TW200640457A/zh
Priority to UY29386A priority patent/UY29386A1/es
Priority to PCT/FR2006/000376 priority patent/WO2006087481A1/fr
Priority to BRPI0608183-5A priority patent/BRPI0608183A2/pt
Priority to AU2006215444A priority patent/AU2006215444A1/en
Priority to EA200701781A priority patent/EA011618B1/ru
Priority to KR1020077018993A priority patent/KR20070104913A/ko
Priority to MX2007009996A priority patent/MX2007009996A/es
Priority to EP06709344A priority patent/EP1853264A1/fr
Priority to JP2007555669A priority patent/JP2008530189A/ja
Priority to CA002597245A priority patent/CA2597245A1/fr
Priority to ARP060100611A priority patent/AR053812A1/es
Publication of FR2882265A1 publication Critical patent/FR2882265A1/fr
Priority to TNP2007000297A priority patent/TNSN07297A1/en
Priority to US11/832,865 priority patent/US20080015229A1/en
Priority to CR9293A priority patent/CR9293A/es
Priority to IL185401A priority patent/IL185401A0/en
Priority to MA30158A priority patent/MA29262B1/fr
Priority to NO20074767A priority patent/NO20074767L/no
Publication of FR2882265B1 publication Critical patent/FR2882265B1/fr
Application granted granted Critical
Priority to US12/402,988 priority patent/US20090197917A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilisation d'un composé antagoniste des récepteurs CB1 aux cannabinoïdes, dérivé du pyrazole, seul ou associé à un autre principe actif, pour la préparation de médicaments utiles dans la prévention et le traitement du diabète de type 2 ou diabète non insulino-dépendant et/ou de ses complications.
FR0505228A 2005-02-21 2005-05-23 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2. Expired - Fee Related FR2882265B1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FR0505228A FR2882265B1 (fr) 2005-02-21 2005-05-23 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.
JP2007555669A JP2008530189A (ja) 2005-02-21 2006-02-20 ２型糖尿病の防止および処置において使用することができる医薬品を調製するためのリモナバントの使用
UY29386A UY29386A1 (es) 2005-02-21 2006-02-20 Utilizción de rimonabant para la preparación de medicamentos útiles en la prevención y el tratamiento de la diabetes de tipo2.
PCT/FR2006/000376 WO2006087481A1 (fr) 2005-02-21 2006-02-20 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
BRPI0608183-5A BRPI0608183A2 (pt) 2005-02-21 2006-02-20 utilização do rimonabante para o preparo de medicamentos úteis na prevenção e no tratamento do diabetes do tipo 2
AU2006215444A AU2006215444A1 (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
EA200701781A EA011618B1 (ru) 2005-02-21 2006-02-20 Применение римонабанта для получения лекарственных средств, пригодных для профилактики и лечения диабета типа 2
KR1020077018993A KR20070104913A (ko) 2005-02-21 2006-02-20 2형 당뇨병의 예방 및 치료에 사용될 수 있는 약제의제조를 위한 리모나반트의 용도
MX2007009996A MX2007009996A (es) 2005-02-21 2006-02-20 Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo 2.
EP06709344A EP1853264A1 (fr) 2005-02-21 2006-02-20 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
TW095105631A TW200640457A (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes
CA002597245A CA2597245A1 (fr) 2005-02-21 2006-02-20 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
ARP060100611A AR053812A1 (es) 2005-02-21 2006-02-21 Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo2
TNP2007000297A TNSN07297A1 (en) 2005-02-21 2007-07-31 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
US11/832,865 US20080015229A1 (en) 2005-02-21 2007-08-02 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes
CR9293A CR9293A (es) 2005-02-21 2007-08-07 Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo 2
IL185401A IL185401A0 (en) 2005-02-21 2007-08-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
MA30158A MA29262B1 (fr) 2005-02-21 2007-08-23 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
NO20074767A NO20074767L (no) 2005-02-21 2007-09-18 Anvendelse av rimonabant for fremstilling av medikamenter som kan anvendes i forebygging og behandling av type 2 diabetes
US12/402,988 US20090197917A1 (en) 2005-02-21 2009-03-12 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (fr) 2005-02-21 2005-02-21 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0504942A FR2882264A1 (fr) 2005-02-21 2005-05-12 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0505228A FR2882265B1 (fr) 2005-02-21 2005-05-23 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.

Publications (2)

Publication Number Publication Date
FR2882265A1 true FR2882265A1 (fr) 2006-08-25
FR2882265B1 FR2882265B1 (fr) 2009-02-13

Family

ID=36809538

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0504942A Withdrawn FR2882264A1 (fr) 2005-02-21 2005-05-12 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0505228A Expired - Fee Related FR2882265B1 (fr) 2005-02-21 2005-05-23 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0504942A Withdrawn FR2882264A1 (fr) 2005-02-21 2005-05-12 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2

Country Status (10)

Country Link
JP (1) JP2008530189A (fr)
BR (1) BRPI0608183A2 (fr)
CR (1) CR9293A (fr)
EA (1) EA011618B1 (fr)
FR (2) FR2882264A1 (fr)
IL (1) IL185401A0 (fr)
MA (1) MA29262B1 (fr)
MX (1) MX2007009996A (fr)
TN (1) TNSN07297A1 (fr)
TW (1) TW200640457A (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046209A1 (fr) * 1999-02-01 2000-08-10 Sanofi-Synthelabo Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046209A1 (fr) * 1999-02-01 2000-08-10 Sanofi-Synthelabo Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Rimonabant-Studie: Signifikante Verbesserungen der HbA1c-Werte", INTERNET ARTICLE, XP002339554, Retrieved from the Internet <URL:http://www.diabetes-news.de/news/nachrichten-2005/pm050617.htm> [retrieved on 20050804] *
HAMANN A ET AL: "Oral diabetes treatment: Which substance is indicated at which time?", INTERNIST 2004 GERMANY, vol. 45, no. 12, 2004, pages 1356 - 1363, XP002339555, ISSN: 0020-9554 *
J-M M: "Rimonabant: nouvelle classe therapeutique multi-effets en prevention cardiovasculaire", REVUE FRANÇAISE DES LABORATOIRES, EDITIONS SCIENTIFIQUES ET MEDICALES ELSEVIER, vol. 2004, no. 367, November 2004 (2004-11-01), pages 11, XP004816553, ISSN: 0338-9898 *
POIRIER B ET AL: "THE ANTI-OBESITY EFFECT OF RIMONABANT IS ASSOCIATED WITH AN IMPROVED SERUM LIPID PROFILE", DIABETES, OBESITY AND METABOLISM, BLACKWELL SCIENCE, OXFORD, GB, vol. 7, no. 1, January 2005 (2005-01-01), pages 65 - 72, XP008047132, ISSN: 1462-8902 *

Also Published As

Publication number Publication date
FR2882264A1 (fr) 2006-08-25
IL185401A0 (en) 2008-08-07
EA200701781A1 (ru) 2007-12-28
CR9293A (es) 2007-10-01
MX2007009996A (es) 2007-10-10
TNSN07297A1 (en) 2008-12-31
JP2008530189A (ja) 2008-08-07
TW200640457A (en) 2006-12-01
MA29262B1 (fr) 2008-02-01
EA011618B1 (ru) 2009-04-28
BRPI0608183A2 (pt) 2009-11-17
FR2882265B1 (fr) 2009-02-13

Similar Documents

Publication Publication Date Title
WO2006047516A3 (fr) Composes et compositions servant d&#39;inhibiteurs d&#39;activite de recepteur cannabinoide de type 1
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l&#39;activité du récepteur cannabinoïde 1
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
WO2003105800A3 (fr) Forme galenique, se presentant sous forme de film adherant a la muqueuse, pour l&#39;administration de principes actifs du cannabis
MA27997A1 (fr) Composes et compositions inhibiteurs de l&#39;activite du recepteur tyrosine kinase
MA30504B1 (fr) Compositions pharmaceutiques stabilisees comprenant de la fesoterodine
BR0312093A (pt) Combinação de substâncias ativas fungicida
MA28269A1 (fr) Arylpyrazoles substitués servant d&#39;agents parasiticides
WO2006044362A3 (fr) Antagonistes du recepteur 1 de n-sulfonylpiperidine cannabinoide
ATE430743T1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
DK0743852T3 (da) Behandling af glaukom med normalt tryk med valsartan
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
WO2007092469A3 (fr) Combinaison de composes organiques
MA28105A1 (fr) Utilisation d&#39;un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l&#39;obesite
MA32602B1 (fr) Utilisation de dronedarone pour la preparation d&#39;un medicament pour la prevention d&#39;un accident vasculaire cerebral ou un accident ischemique transitoire
EP1774968A4 (fr) Dérivé de benzylisoquinoléine - ou dérivé bisbenzylisoquinoléine - contenant un agent psychotrope, analgésique et/ou antiphlogistique, et aliment de santé.
BRPI0509645A (pt) comprimidos dispensáveis de deferasirox
FR2902010B1 (fr) Utilisation de la 1,7 dimethylxanthine pour la fabrication d&#39;un medicament psychoanaleptique non anxiogene destine au traitement d&#39;un trouble neuropsychiatrique
FR2891460B1 (fr) Utilisation d&#39;au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
MA29263B1 (fr) Utilisation d&#39;un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
FR2882265A1 (fr) Utilisation d&#39;un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.
WO2007017126A3 (fr) Polymorphe d&#39;une pyrazoline substituee, sa preparation et son utilisation comme medicaments
CA2461625A1 (fr) Irbesartan entrant dans la preparation des produits medicaux utiles pour prevenir ou traiter l&#39;hypertension arterielle pulmonaire
CA2534833A1 (fr) Derives de la benzimidazolone et de la quinazolinone a substitution bicyclo[3.1.1]heptane en tant qu&#39;agonistes du recepteur orl1 humain

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20110131